Thomas Jefferson University

Jefferson Digital Commons
Department of Pharmacology and Experimental Department of Pharmacology and Experimental
Therapeutics Posters
Therapeutics
3-17-2017

Population Pharmacokinetic and Pharmacodynamic Analysis of
Buprenorphine for the Treatment of Neonatal Abstinence
Syndrome
Jason N. Moore, PharmD
Thomas Jefferson University

Marc Gastonguay
Metrum Research Group, Tariffville, CT

Susan C. Adeniyi-Jones, MD
Thomas Jefferson University

David E. Moody
University of Utah
Follow this and additional works at: https://jdc.jefferson.edu/petposters

Walter K. Kraft, MD, FACP

Part of the Pharmacy and Pharmaceutical Sciences Commons
Thomas Jefferson University

Let us know how access to this document benefits you
Recommended Citation
Moore, PharmD, Jason N.; Gastonguay, Marc; Adeniyi-Jones, MD, Susan C.; Moody, David E.; and Kraft, MD,
FACP, Walter K., "Population Pharmacokinetic and Pharmacodynamic Analysis of Buprenorphine for the
Treatment of Neonatal Abstinence Syndrome" (2017). Department of Pharmacology and Experimental
Therapeutics Posters. 4.
https://jdc.jefferson.edu/petposters/4

This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital
Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is
a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections
from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested
readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been
accepted for inclusion in Department of Pharmacology and Experimental Therapeutics Posters by an authorized
administrator of the Jefferson Digital Commons. For more information, please contact:
JeffersonDigitalCommons@jefferson.edu.

Population Pharmacokinetic and Pharmacodynamic Analysis of Buprenorphine for the Treatment of Neonatal
Abstinence Syndrome
Jason N. Moore(1), Marc Gastonguay(2) , Susan Adeniyi-Jones(3), David E. Moody(4), Walter K. Kraft(1)
(1) Thomas Jefferson University – Department of Pharmacology and Experimental Therapeutics, Philadelphia, PA; (2) Metrum Research Group,
Tariffville, CT; (3) Thomas Jefferson University/Nemours, Philadelphia, PA; (4) University of Utah, Salt Lake City, UT.
Introduction
Neonatal abstinence syndrome (NAS) is a condition affecting newborns
exposed to an opioid in utero. Symptoms of NAS include excessive crying,
poor feeding, and disordered autonomic control. Up to 2/3 of infants will
require pharmacologic therapies to reach symptom control. Opioids
including morphine and methadone are the current first-line treatments.
Buprenorphine is being investigated as a treatment of NAS. The purpose of
this analysis was to evaluate the pharmacokinetics (PK) and
pharmacodynamics (PD) of BUP in infants with NAS.

Methods
The Blinded Buprenorphine OR Neonatal morphine solution (BBORN) trial
(NCT01452789) was a double-blind, double-dummy, randomized, controlled
trial that assessed the efficacy of buprenorphine and morphine in NAS.
Blood was analyzed from patients who received buprenorphine. All infants
were monitored using the MOTHER NAS Scale, a modified Finnegan scoring
instrument.
Term infants were treated for NAS if they had 3 scores >24 or a single score
>12. The neonates allocated to the buprenorphine group were treated with
sublingual buprenorphine 5.3 µg/kg every eight hours. Doses were uptitrated by 25% for inadequate symptom control up to a maximal dose of 20
µg/kg.
When the infant was stabilized, the dose was tapered at a rate of 10% daily
until within 10% of the starting dose. Blood for PK analysis was drawn in all
study patients using a sparse sampling regimen. Buprenorphine and
norbuprenorphine
concentrations
were
analyzed
using
liquid
chromatography/mass spectrometry. The limit of quantification was 0.1
ng/mL for both buprenorphine and norbuprenorphine.
The data were used to validate and adapt an existing model of
buprenorphine PK in neonates (Ng CM,. Pharmacotherapy. 2015
Jul;35(7):670-80. PMID 26172282). This reference model utilized a 2compartment model with PK parameters scaled allometrically by weight and
maturation functions on clearance and peripheral volume of distribution.
The model was then extended to norbuprenorphine. Norbuprenorphine
formation was modeled as a fraction of previously established clearance of
buprenorphine given the potential for buprenorphine to be metabolized by
multiple pathways. The metabolite PK parameters were also scaled by
weight allometrically. The buprenorphine/norbuprenorphine data were
analyzed against the NAS scores to identify potential PD relationships. The
knowledge of the relationship was used to link the PK to a PD model of NAS.

Results
Patient Demographics

Figure 2. Buprenorphine GOF

Figure 3. Norbuprenorphine GOF

Figure 4. NAS Score GOF

172 buprenorphine/norbuprenorphine serum
concentrations and 4373 NAS scores were
collected from 28 full term infants. The
reference model from a Phase 1 trial was shown
to reasonably predict the new data with mean
squared error of 0.062 and root mean squared
error of 0.251.

PK and PD Model Parameters
The goodness-of-fit (GOF) plots demonstrate that the model was generally able to describe the data well.

Figure 8. NAS Predictive Checks
Figure 5. Relationship Between Clearance
of Buprenorphine and Time to Stabilization

Figure 6. NAS Severity Influenced Required Buprenorphine
Exposure

Figure 7. Relationship Between Average Concentration
of Buprenorphine and Time to Stabilization

Exposure to buprenorphine drives clinical efficacy in
NAS. The graphs show that time to stabilization of NAS
was linked to the initial severity of NAS and the total
exposure to buprenorphine. In Figure 5, neonates with
higher clearances were exposed to less study agent
and had higher times to stabilization. Figure 6 shows
that more severe NAS generally required a higher AUC
of buprenorphine to stabilize. Figure 7 demonstrates
that higher average concentrations of buprenorphine
were correlated with faster time to stabilization.

Figure 1. PK and PD Model Schematic

a) 1000 simulations of average NAS score. The solid line
and blue shaded area represent the median and 95% CI
of the simulation, and the dashed lines represent the
median and 95% CI of the observed data.
b) Histogram of 1000 simulated times to stabilization with
the dotted lines as the median and 95% CI of the
simulation. Black line is median of the observed data.
These graphs further demonstrate that the PD model was
effective in the description of the course of NAS and
the time to stabilization.

Conclusions
• The findings confirm an existing PK model of buprenorphine in neonates and extend the model to describe the PK of norbuprenorphine and the PD of buprenorphine in NAS.
• This is the first PD model of a drug effect in NAS. It appeared to well describe relevant features of the NAS disease course.
• Exposure to buprenorphine was linked to stabilization of NAS. Clearance as the inverse of exposure appeared to be the primary driver of clinical efficacy.

Future Directions
• This PK-PD model can be used to simulate dose regimens which may facilitate quicker stabilization or less frequent dosing.
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